You are here:

pemetrexed (Alimta)

Advice

following a full submission assessed under the end of life process.

pemetrexed (Alimta®) is accepted for use within NHS Scotland.

Indication under review: monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

In patients with locally advanced or metastatic non-squamous non-small cell lung cancer, maintenance treatment with pemetrexed, following completion of first-line platinum-based chemotherapy, was associated with prolonged overall survival and progression-free survival when compared with placebo.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: pemetrexed (Alimta)
SMC Drug ID: 770/12
Manufacturer: Eli Lilly and Company Ltd
Indication: monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 December 2014

Archived Advice

Non submission 13 February 2012

Back